Targeting cell cycle and hormone receptor pathways in cancer

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

(2012) J. P. Leonard et al.   BLOOD

Evidence for Efficacy of New Hsp90 Inhibitors Revealed by Ex Vivo Culture of Human Prostate Tumors

(2012) M. M. Centenera et al.   CLINICAL CANCER RESEARCH

Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy

(2012) Patrick J. Roberts et al.   JNCI-Journal of the National Cancer Institute

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)

(2011) G K Schwartz et al.   BRITISH JOURNAL OF CANCER

Deregulation of FGFR1 and CDK6 oncogenic pathways in acute lymphoblastic leukaemia harbouring epigenetic modifications of the MIR9 family

(2011) Paula Rodriguez-Otero et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Systematic Screen for CDK4/6 Substrates Links FOXM1 Phosphorylation to Senescence Suppression in Cancer Cells

(2011) Lars Anders et al.   CANCER CELL

Early G1 Cyclin-Dependent Kinases as Prognostic Markers and Potential Therapeutic Targets in Esophageal Adenocarcinoma

(2011) A. Ismail et al.   CLINICAL CANCER RESEARCH

Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer

(2011) K. T. Flaherty et al.   CLINICAL CANCER RESEARCH

Modeling a Lethal Prostate Cancer Variant with Small-Cell Carcinoma Features

(2011) V. Tzelepi et al.   CLINICAL CANCER RESEARCH

[18F]FLT–PET Imaging Does Not Always “Light Up” Proliferating Tumor Cells

(2011) Cathy C. Zhang et al.   CLINICAL CANCER RESEARCH

Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer

(2011) Gottfried E. Konecny et al.   CLINICAL CANCER RESEARCH

Pharmacotherapeutic Management of Locally Advanced Prostate Cancer

(2011) Jarad M. Martin et al.   DRUGS

Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer

(2011) C. Thangavel et al.   ENDOCRINE-RELATED CANCER

mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer

(2011) Matthew J Schiewer et al.   ENDOCRINE-RELATED CANCER

New Hormonal Therapies for Castration-Resistant Prostate Cancer

(2011) Elahe A. Mostaghel et al.   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

Cyclin D1 Is a Selective Modifier of Androgen-dependent Signaling and Androgen Receptor Function

(2011) Clay E. S. Comstock et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Common Gene Rearrangements in Prostate Cancer

(2011) Mark A. Rubin et al.   JOURNAL OF CLINICAL ONCOLOGY

The AR dependent cell cycle: Mechanisms and cancer relevance

(2011) Matthew J. Schiewer et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

A Robust High-Content Imaging Approach for Probing the Mechanism of Action and Phenotypic Outcomes of Cell-Cycle Modulators

(2011) J. J. Sutherland et al.   MOLECULAR CANCER THERAPEUTICS

A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers

(2011) Siwanon Jirawatnotai et al.   NATURE

Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer

(2011) Ana Aparicio et al.   Nature Reviews Urology

A bioinformatical and functional approach to identify novel strategies for chemoprevention of colorectal cancer

(2011) D M Heijink et al.   ONCOGENE

ER -Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer

(2011) T. W. Miller et al.   Cancer Discovery

A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma

(2010) Marta Puyol et al.   CANCER CELL

Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts

(2010) K. Michaud et al.   CANCER RESEARCH

Cyclin D2-Cyclin-Dependent Kinase 4/6 Is Required for Efficient Proliferation and Tumorigenesis following Apc Loss

(2010) A. M. Cole et al.   CANCER RESEARCH

Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor–chemotherapy combinations as an anticancer strategy for solid tumors

(2010) Neil Johnson et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Proliferative Suppression by CDK4/6 Inhibition: Complex Function of the Retinoblastoma Pathway in Liver Tissue and Hepatoma Cells

(2010) Dayana B. Rivadeneira et al.   GASTROENTEROLOGY

Whether to target single or multiple CDKs for therapy? That is the question

(2010) Józefa Węsierska-Gądek et al.   JOURNAL OF CELLULAR PHYSIOLOGY

The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression

(2010) Ankur Sharma et al.   JOURNAL OF CLINICAL INVESTIGATION

Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure

(2010) J L Dean et al.   ONCOGENE

Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM

(2010) W. R. Wiedemeyer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The E2F1/Rb and p53/MDM2 Pathways in DNA Repair and Apoptosis: Understanding the Crosstalk to Develop Novel Strategies for Prostate Cancer Radiotherapy

(2010) Thirupandiyur Udayakumar et al.   SEMINARS IN RADIATION ONCOLOGY

Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer

(2009) Qianben Wang et al.   CELL

Cyclin-dependent kinase inhibitors as potential targeted anticancer agents

(2009) Ivan Diaz-Padilla et al.   INVESTIGATIONAL NEW DRUGS

Treatment of Growing Teratoma Syndrome

(2009) David J. Vaughn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Crystal structure of human CDK4 in complex with a D-type cyclin

(2009) P. J. Day et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Novel Therapeutic Combination Using PD 0332991 and Bortezomib: Study in the 5T33MM Myeloma Model

(2008) E. Menu et al.   CANCER RESEARCH

Advancing Bioluminescence Imaging Technology for the Evaluation of Anticancer Agents in the MDA-MB-435-HAL-Luc Mammary Fat Pad and Subrenal Capsule Tumor Models

(2008) C. Zhang et al.   CLINICAL CANCER RESEARCH